Loading patent…
AssigneeAllogene Therapeutics, Inc.
InventorsMichael Thomas Bethune, Eric Hans Gschweng, Thomas John Van Blarcom, Cesar Adolfo Sommer
Estimating the term…
Compositions, methods, expression vectors and engineered immune cells for improving therapies that entail the administration of allogeneic cells to a patient. An immune cell, e.g., a T cell, modified to comprise and/or express FasL protein or a FasL protein derivative from, for example, an expression vector comprising a polynucleotide that encodes FasL protein or a FasL protein derivative, and to express FasR at a reduced level, and further modified to comprise and/or express an antigen binding protein e.g., a chimeric antigen receptor (CAR). An improved method of CAR T-cell therapy that comprises administering the improved immune cells, and compositions that comprise the improved immune cells. Methods of improving persistence of administered cells and reducing activation-induced cell death comprising administering the improved cells.
An engineered immune cell comprising a vector, wherein the vector comprises a polynucleotide encoding an antigen binding protein and a polynucleotide encoding a FasL derivative selected from the group consisting of FasL Q130D (SEQ ID NO:
A method of treating a condition in a patient wherein the condition is selected from the group consisting of a viral disease, a bacterial disease, a cancer, an inflammatory disease, and an immune disease, the method comprising intravenously administering to the patient therapeutically effective population of engineered T cells expressing an antigen binding protein and a Fas ligand (FasL) derivative selected from the group consisting of FasL Q130D (SEQ ID NO:
A method for reducing host cell killing of allogeneic cells in a therapeutic regimen comprising administering allogeneic cells to a patient, the method comprising intravenously administering to the patient a therapeutically effective population of engineered T-cells expressing an antigen binding protein and a FasL derivative selected from the group consisting of FasL Q130D (SEQ ID NO:
A method of enhancing the persistence of allogeneic cells in a patient comprising intravenously administering allogeneic cells to a patient, the method comprising administering to the patient a therapeutically effective population of engineered T cells expressing an antigen binding protein and a FasL derivative selected from the group consisting of FasL Q130D (SEQ ID NO:
Dependencies are inferred from the claim text.